Supernus Pharmaceuticals (SUPN) Prepaid Assets (2011 - 2026)
Supernus Pharmaceuticals' (SUPN) quarterly Prepaid Assets came in at $78.1 million in Q1 2026, up 169.93% year-on-year from $28.9 million in Q1 2025, and up 19.55% on a QoQ basis from $65.3 million in Q4 2025.
Supernus Pharmaceuticals (SUPN) Prepaid Assets (2011 - 2026) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 16 years of Prepaid Assets data on file, last reported at $78.1 million in Q1 2026.
- On a quarterly basis, Prepaid Assets rose 169.93% year-over-year to $78.1 million in Q1 2026; TTM through Mar 2026 was $78.1 million, a 169.93% increase from a year earlier, with the FY2025 full-year figure at $65.3 million, up 81.02% from the prior year.
- Prepaid Assets for Q1 2026 stood at $78.1 million, up from $65.3 million in the prior quarter.
- Over the last five years, Prepaid Assets for SUPN reached as high as $78.1 million in Q1 2026 and fell as low as $15.8 million in Q4 2022.
- Historically, Prepaid Assets has averaged $33.1 million across 5 years, with a median of $24.8 million in 2022.
- Across the five-year window, Prepaid Assets slumped 48.25% in 2024 and surged 169.93% in 2026, its largest moves.
- Year by year, Prepaid Assets stood at $15.8 million in 2022, then gained by 5.68% to $16.7 million in 2023, then soared by 116.41% to $36.1 million in 2024, then jumped by 81.02% to $65.3 million in 2025, then rose by 19.55% to $78.1 million in 2026.
- Per Business Quant data, the three most recent Prepaid Assets figures were $78.1 million in Q1 2026, $65.3 million in Q4 2025, and $62.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Supernus Pharmaceuticals | 2.72 Bn | 2.34 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 78.09 Mn |
| Dec 31, 2025 | 65.33 Mn |
| Sep 30, 2025 | 62.08 Mn |
| Jun 30, 2025 | 31.42 Mn |
| Mar 31, 2025 | 28.93 Mn |
| Dec 31, 2024 | 36.09 Mn |
| Sep 30, 2024 | 27.40 Mn |
| Jun 30, 2024 | 23.17 Mn |
| Mar 31, 2024 | 23.77 Mn |
| Dec 31, 2023 | 16.68 Mn |
| Sep 30, 2023 | 23.93 Mn |
| Jun 30, 2023 | 44.77 Mn |
| Mar 31, 2023 | 16.30 Mn |
| Dec 31, 2022 | 15.78 Mn |
| Sep 30, 2022 | 24.85 Mn |
| Jun 30, 2022 | 21.41 Mn |
| Mar 31, 2022 | 22.37 Mn |
| Dec 31, 2021 | 27.02 Mn |
| Sep 30, 2021 | 30.69 Mn |
| Jun 30, 2021 | 33.74 Mn |